Today we report in Nature Genetics the genetic landscape of cancer drug resistance mechanisms from CRISPR base editing screens nature.com/articles/s4158…

Approved NSCLC drugs since 2011. Very informative table from CCR. aacrjournals.org/clincancerres/…

Analysis of Big Pharma Therapeutic M&A Deals from 2019 to today Some takeaways: • M&A tends to pick up as company's approach big LOEs, and so unsurprisingly, Merck and AbbVie led the way. For Merck, they're facing a $30B LOE in 2028 with Keytruda - big bets on Acceleron

Drug discovery is hard! Despite decades of efforts, there's still only one target in the DNA damage response with an approved inhibitor: PARP

#CARTcells for #DIPG #DMG clinical trial (1st arm) results are out today. Full Tweetorial coming, but first want to share the story of a patient whose #DIPG has disappeared for over 3 years. It is a milestone and moment of hope on a journey filled with so much grief. “There’s a

💡T-CELL ENGAGER CONSIDERATIONS CD3 is indeed internalized by T cells as part of the T cell receptor (TCR) complex, which can affect the functionality of T cell engagers (TCEs). 🎯CD3 Internalization Upon activation, the TCR-CD3 complex gets internalized through endocytosis.

#SUO24 TiP Ph 1 dose escalation trial of zalifrelimab (UGN-301; anti-CTLA-4 mAB RTgel) for BCG-unresponsive/intolerant HG Ta/T1/CIS NMIBC or HG Ta ≤3 cm & failed 1 prior course of intravesical therapy 3 arm trial: - Arm A: UGN-301 monotherapy - Arm B: UGN-301 + UGN-201

UR001: a phase 1 dose-escalation study of UGN-301 (Zalifrelimab) in patients with recurrent #NMIBC. Presentation by Marco Maruzzo IOV - Istituto Oncologico Veneto. #SUO24 written coverage by Zach Klaassen Georgia Cancer Center on UroToday > bit.ly/3B5MFSB Society of Urologic Oncology

Two CDK4/6 inhibitors are approved for select patients w/ high-risk HR+, HER2-#EarlyBreastCancer. Understanding the design of CDK4/6i adjuvant trials can help HCPs optimize treatment plans. #BCSM 📚Explore our library of EBC educational resources here: e.lilly/4flHagy

Cancer Chemotherapy #meded #medx #chemotherapy #cancer #oncology #TICMED25 OncoDaily OncoAlert

AI will do a lot of good things. But it won't cure cancer. Here are a few reasons why 1. AI is trained on the best available published literature. If you have AI read all of the papers in cancer, you have just had AI read 50% or more of literature that cannot be reproduced or

⌛️Tic Toc - pharma needs M&A to offset the upcoming mountain of patent expirations Source: Sleuth

New results from the CREST Study (NCT04165317) for HR-NMIBC: Adding sasanlimab to BCG induction + maintenance shows: •32% ⬇️of EFS event (HR 0.68, p=0.0095) •>50% reduction in HG recurrence •No difference in overall survival (OS interim HR 1.13, p=0.6791) #AUA25 #bladdercancer

⚠️Paradigm shifts in NMIBC #AUA2025 BCG naive : sasanlimab + BCG > BCG BCG REFRACTORY: intravesical tt - docetaxel/gemcitabine - cretostimogene grenadenorepvec - gemcitabine with TAR-200 delivery SUNRISE1( CIS : 1 year data presented ; papillary : cohort 4 early data)

1/2 RIII CREST: BCG + sasanlimab vs BCG = ⬆️ EFS by 32% (HR=0.68,min FU 3yrs,n=1050). ⬇️ recurrent high risk NMIBC was the predominant feature. No OS signal. Enrichment in relevant subgroups such as CIS (HR=0.53). Tox: 29% v 6% G3-4 TRAEs is part of risk/benefit decision #AUA25

2/2) 2 yrs of subcut sasanlimab = ~10% chance of problematic/life changing immune tox. EFS includes serious cancer risk (MIBC, advanced disease, UC death), but also HG NMIBC. An unselected approach will mean over treatment for some. Delivery in urology clinics requires planning.

TAR-200 monotherapy in patients with BCG–unresponsive high-risk #NMIBC carcinoma in situ: 1-year durability and patient-reported outcomes from SUNRISE-1 trial. Presented by Joseph Jacob, MD, MCR Upstate Cancer Center. #AUA25 written coverage by Julian Chavarriaga University of Toronto >

TAR-200 monotherapy in patients with BCG–unresponsive papillary disease–only high-risk #NMIBC: first results from cohort 4 of SunRise-1. Presented by Félix Guerrero-Ramos. #AUA25 written coverage by Julian Chavarriaga > bit.ly/3GHjCa0 Amer. Urol. Assn. J&J Medical Affairs Oncology

$URGN UroGen Pharma announces results from Phase 1 study of UGN-301 UroGen Pharma announced encouraging safety data from the Phase 1 dose-escalation study for UGN-301 intravesical solution, an investigational drug in development for the treatment of recurrent non-muscle invasive